Lucis, a Paris-based preventive health platform, raised a $20m Series A on 26 May 2026. Singular led the round, with participation from General Catalyst, Y Combinator and angel investors. The angels include backers of the running-coach app Runna, Céline Lazorthes of Resilience, and Manu Lecomte.
The round came four months after a seed round. The company's own announcement put the seed at $8m, while The Next Web said it was $8.5m and closed in December 2025. Total funding is about $28m. Lucis did not disclose a valuation.
“Europe’s preventive health category will be won by platforms that unite clinical credibility with AI at scale.”Jeremy Uzan, Co-Founder and General Partner, Singular
What Lucis does
Lucis was founded in 2025 by Maxime Berthelot, who is chief executive, and Baptiste Debever. The Next Web also named Max Guérois as a co-founder and said the company went through Y Combinator's 2025 batch.
Members have blood drawn at a partner laboratory, and the platform analyses more than 110 biomarkers across systems including metabolic health, hormones, cardiovascular risk, inflammation and nutrient levels. The results feed an AI companion app that recommends changes to nutrition, supplements and lifestyle and suggests follow-up tests. Physicians review the recommendations. Laboratory partners include Eurofins and Randox.
Lucis's website lists memberships from €199 a year, covering more than 80 biomarkers, a doctor-reviewed plan and an AI coach.
Usage figures
The company said it has more than 10,000 users in France, the UK, Ireland and Portugal, and has run over one million biomarker tests. It said that among users who completed a six-month follow-up, 75% improved at least three biomarkers without medication, and more than 80% chose to retest. It also said 99.9% of users had at least one biomarker outside its optimal ranges at their first test.
The Next Web noted that these numbers are supplied by the company and have not been independently audited. It also observed that the tests themselves are commodity work done by certified labs, so the company's case rests on its AI layer and long-term tracking, and on whether engagement turns into retention.
Team and plans
Lucis has a team of 20 across engineering, clinical, growth and operations, plus a medical board and a network of more than ten physicians who provide clinical oversight, according to the announcement.
The company plans to expand into Spain, Germany and Italy by the end of 2026, and to keep investing in personalisation, longitudinal monitoring and clinical safety. The Next Web said the money will also fund continued development of the AI layer that turns biomarker data into ongoing guidance.
Competition and investor view
The Next Web placed Lucis alongside Function Health, Superpower, Forward and Berlin's HealthCaters, which are betting that consumers will pay to track their own biomarkers before any clinical reason arises.
Jeremy Uzan, co-founder and general partner at Singular, said Lucis had moved with remarkable velocity, reaching 10,000 users in under a year. Berthelot said the science is already there and what is missing is a system designed to act before symptoms appear.
Company website: lucis.life